SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001347178-19-000011
Filing Date
2019-05-03
Accepted
2019-05-03 07:02:25
Documents
86
Period of Report
2019-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q vnda331201910q.htm 10-Q 953795
2 EXHIBIT 31.1 vndaex311331201910q.htm EX-31.1 13568
3 EXHIBIT 31.2 vndaex312331201910q.htm EX-31.2 13536
4 EXHIBIT 32.1 vndaex321331201910q.htm EX-32.1 9460
  Complete submission text file 0001347178-19-000011.txt   5701649

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT vnda-20190331.xml EX-101.INS 1058058
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vnda-20190331.xsd EX-101.SCH 56964
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT vnda-20190331_cal.xml EX-101.CAL 97124
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT vnda-20190331_def.xml EX-101.DEF 233594
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vnda-20190331_lab.xml EX-101.LAB 649461
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vnda-20190331_pre.xml EX-101.PRE 405992
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

IRS No.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34186 | Film No.: 19794023
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences